Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample

Robert Lehmann,1 Andrew Maxwell,2 David M Lubeck,3 Raymond Fong,4 Thomas R Walters,5 Anna Fakadej6 1Lehmann Eye Center, Nacogdoches, TX, USA; 2California Eye Institute, Fresno, CA, USA; 3Arbor Centers for EyeCare, Homewood, IL, USA; 4Manhattan Eye, Ear, and Throat Hospital, Lenox Hill Hospital, New...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lehmann R, Maxwell A, Lubeck DM, Fong R, Walters TR, Fakadej A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	glistenings posterior capsule opacification visual acuity cystoid macular edema dysphotopsia Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/94d7d79311bd400a80e081e21a6274ce
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:94d7d79311bd400a80e081e21a6274ce
record_format	dspace
spelling	oai:doaj.org-article:94d7d79311bd400a80e081e21a6274ce2021-12-02T14:28:03ZEffectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample1177-5483https://doaj.org/article/94d7d79311bd400a80e081e21a6274ce2021-04-01T00:00:00Zhttps://www.dovepress.com/effectiveness-and-safety-of-the-clareon-monofocal-intraocular-lens-out-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Robert Lehmann,1 Andrew Maxwell,2 David M Lubeck,3 Raymond Fong,4 Thomas R Walters,5 Anna Fakadej6 1Lehmann Eye Center, Nacogdoches, TX, USA; 2California Eye Institute, Fresno, CA, USA; 3Arbor Centers for EyeCare, Homewood, IL, USA; 4Manhattan Eye, Ear, and Throat Hospital, Lenox Hill Hospital, New York, NY, USA; 5Texan Eye, Austin, TX, USA; 6Carolina Eye Associates, PA, Southern Pines, NC, USACorrespondence: Robert LehmannLehmann Eye Center, Nacogdoches, TX, USATel +1 936-569-8278Email doctorlehmann@me.comPurpose: This study assessed effectiveness and safety of the novel Clareon intraocular lens (IOL; model SY60CL; Alcon Vision LLC).Patients and Methods: This was a prospective, single-arm, unmasked clinical trial at 16 investigative clinical sites in the United States. Included were adults ≥ 22 years who required cataract extraction by phacoemulsification. Following phacoemulsification, 350 subjects received SY60CL IOL unilaterally; 342 completed the study. Monocular best corrected distance visual acuity (CDVA) and uncorrected distance visual acuity (UDVA) were evaluated. The primary effectiveness endpoint was the percentage of subjects with CDVA ≤ 0.3 logMAR at month 12. Safety was assessed by monitoring adverse events (AEs). Visual acuity and safety outcomes were compared with historical safety and performance endpoint (SPE) rates.Results: At 12 months post-implantation, 99.7% of subjects receiving the SY60CL IOL achieved monocular CDVA ≤ 0.3 logMAR (primary effectiveness endpoint; 1-sided 95% upper confidence limit >SPE rate); 99.7% and 86.8% of subjects achieved monocular CDVA of ≤ 0.34 (20/40 Snellen or better) and ≤ 0.04 logMAR (20/20 Snellen or better), respectively. At 12 months, > 95% of subjects achieved mean monocular UDVA ≤ 0.3 logMAR; 97.1% and 57.6% of subjects achieved monocular CDVA of ≤ 0.34 and ≤ 0.04 logMAR, respectively. Mean monocular CDVA and UDVA were − 0.05 and 0.04 logMAR, respectively. AEs were within SPE limits. The most common nonserious ocular AE was posterior capsule opacification (5.4%). Serious AEs were < 1%, and no serious ocular AEs were assessed as related to the device. There were no observations for IOL glistenings at 12 months.Conclusion: Results of this study supported effectiveness and safety of the SY60CL IOL. Visual acuity outcomes with the SY60CL IOL exceeded the SPE rates for monocular CDVA and AEs were within the limit of historic SPE rates. (Model number SY60WF is the Clareon lens approved by the FDA.)Keywords: glistenings, posterior capsule opacification, visual acuity, cystoid macular edema, dysphotopsiaLehmann RMaxwell ALubeck DMFong RWalters TRFakadej ADove Medical Pressarticleglisteningsposterior capsule opacificationvisual acuitycystoid macular edemadysphotopsiaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 1647-1657 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	glistenings posterior capsule opacification visual acuity cystoid macular edema dysphotopsia Ophthalmology RE1-994
spellingShingle	glistenings posterior capsule opacification visual acuity cystoid macular edema dysphotopsia Ophthalmology RE1-994 Lehmann R Maxwell A Lubeck DM Fong R Walters TR Fakadej A Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample
description	Robert Lehmann,1 Andrew Maxwell,2 David M Lubeck,3 Raymond Fong,4 Thomas R Walters,5 Anna Fakadej6 1Lehmann Eye Center, Nacogdoches, TX, USA; 2California Eye Institute, Fresno, CA, USA; 3Arbor Centers for EyeCare, Homewood, IL, USA; 4Manhattan Eye, Ear, and Throat Hospital, Lenox Hill Hospital, New York, NY, USA; 5Texan Eye, Austin, TX, USA; 6Carolina Eye Associates, PA, Southern Pines, NC, USACorrespondence: Robert LehmannLehmann Eye Center, Nacogdoches, TX, USATel +1 936-569-8278Email doctorlehmann@me.comPurpose: This study assessed effectiveness and safety of the novel Clareon intraocular lens (IOL; model SY60CL; Alcon Vision LLC).Patients and Methods: This was a prospective, single-arm, unmasked clinical trial at 16 investigative clinical sites in the United States. Included were adults ≥ 22 years who required cataract extraction by phacoemulsification. Following phacoemulsification, 350 subjects received SY60CL IOL unilaterally; 342 completed the study. Monocular best corrected distance visual acuity (CDVA) and uncorrected distance visual acuity (UDVA) were evaluated. The primary effectiveness endpoint was the percentage of subjects with CDVA ≤ 0.3 logMAR at month 12. Safety was assessed by monitoring adverse events (AEs). Visual acuity and safety outcomes were compared with historical safety and performance endpoint (SPE) rates.Results: At 12 months post-implantation, 99.7% of subjects receiving the SY60CL IOL achieved monocular CDVA ≤ 0.3 logMAR (primary effectiveness endpoint; 1-sided 95% upper confidence limit >SPE rate); 99.7% and 86.8% of subjects achieved monocular CDVA of ≤ 0.34 (20/40 Snellen or better) and ≤ 0.04 logMAR (20/20 Snellen or better), respectively. At 12 months, > 95% of subjects achieved mean monocular UDVA ≤ 0.3 logMAR; 97.1% and 57.6% of subjects achieved monocular CDVA of ≤ 0.34 and ≤ 0.04 logMAR, respectively. Mean monocular CDVA and UDVA were − 0.05 and 0.04 logMAR, respectively. AEs were within SPE limits. The most common nonserious ocular AE was posterior capsule opacification (5.4%). Serious AEs were < 1%, and no serious ocular AEs were assessed as related to the device. There were no observations for IOL glistenings at 12 months.Conclusion: Results of this study supported effectiveness and safety of the SY60CL IOL. Visual acuity outcomes with the SY60CL IOL exceeded the SPE rates for monocular CDVA and AEs were within the limit of historic SPE rates. (Model number SY60WF is the Clareon lens approved by the FDA.)Keywords: glistenings, posterior capsule opacification, visual acuity, cystoid macular edema, dysphotopsia
format	article
author	Lehmann R Maxwell A Lubeck DM Fong R Walters TR Fakadej A
author_facet	Lehmann R Maxwell A Lubeck DM Fong R Walters TR Fakadej A
author_sort	Lehmann R
title	Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample
title_short	Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample
title_full	Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample
title_fullStr	Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample
title_full_unstemmed	Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample
title_sort	effectiveness and safety of the clareon monofocal intraocular lens: outcomes from a 12-month single-arm clinical study in a large sample
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/94d7d79311bd400a80e081e21a6274ce
work_keys_str_mv	AT lehmannr effectivenessandsafetyoftheclareonmonofocalintraocularlensoutcomesfroma12monthsinglearmclinicalstudyinalargesample AT maxwella effectivenessandsafetyoftheclareonmonofocalintraocularlensoutcomesfroma12monthsinglearmclinicalstudyinalargesample AT lubeckdm effectivenessandsafetyoftheclareonmonofocalintraocularlensoutcomesfroma12monthsinglearmclinicalstudyinalargesample AT fongr effectivenessandsafetyoftheclareonmonofocalintraocularlensoutcomesfroma12monthsinglearmclinicalstudyinalargesample AT walterstr effectivenessandsafetyoftheclareonmonofocalintraocularlensoutcomesfroma12monthsinglearmclinicalstudyinalargesample AT fakadeja effectivenessandsafetyoftheclareonmonofocalintraocularlensoutcomesfroma12monthsinglearmclinicalstudyinalargesample
_version_	1718391266758098944

Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample

Ejemplares similares